Gut bacteria boost? new trial combines probiotic with cancer therapy for rectal tumors
NCT ID NCT07458529
First seen Mar 14, 2026 · Last updated Jun 22, 2026 · Updated 13 times
Summary
This phase 2 trial is testing whether adding a probiotic called Probio-M9 to standard chemoradiation and an immunotherapy drug (tislelizumab) can improve outcomes for people with locally advanced rectal cancer. About 50 participants will be randomly assigned to receive either the probiotic or a placebo alongside their cancer treatment before surgery. The main goal is to see if the probiotic helps more tumors completely disappear after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seventh Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Probio-M9 (a probiotic) and tislelizumab (an immunotherapy drug)
What this could lead to
If it works, this could lead to a more effective pre-surgery treatment for certain rectal cancers, potentially increasing the chance of complete tumor disappearance.
What could go wrong
This is a small, early-phase trial (50 people) at a single center. The probiotic may not add benefit, and immunotherapy can cause immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.